The 3rd Canadian Symposium on Hepatitis C Virus: Expanding Care in the Interferon-Free Era by MacParland, Sonya Ann et al.
Can J Gastroenterol Hepatol Vol 28 No 9 October 2014 481
the 3rd canadian symposium on Hepatitis c Virus: 
expanding care in the interferon-free era
Sonya A MacParland PhD1, Marc Bilodeau MD2, Jason Grebely PhD3, Julie Bruneau MD4, Curtis Cooper MD5,  
Marina Klein MD6, Selena M Sagan PhD7, Norma Choucha2, Louise Balfour PhD5, Frank Bialystok PhD1,  
Mel Krajden MD8,9, Jennifer Raven PhD10, Eve Roberts MD1, Rodney Russell PhD11,  
Michael Houghton PhD12, D Lorne Tyrrell MD PhD12, Jordan J Feld MD1;  
on behalf of the National CIHR Research Training Program in Hepatitis C
1University of Toronto, Toronto, Ontario; 2Liver Unit, Department of Medicine, Université de Montréal, Montréal, Québec; 3The Kirby Institute, 
UNSW Australia, Sydney, Australia; 4Department of Family Medicine, Université de Montréal, Montréal, Québec; 5Division of Infectious Diseases, 
University of Ottawa, Ottawa, Ontario; 6Division of Infectious Diseases; 7Department of Microbiology & Immunology, McGill University, Montreal, 
Quebec; 8British Columbia Centre for Disease Control; 9University of British Columbia, Vancouver, British Columbia; 10Canadian Institutes of Health 
Research – Institute of Infection and Immunity, Ottawa, Ontario; 11Division of Biomedical Sciences, Memorial University of Newfoundland, St John’s, 
Newfoundland & Labrador; 12Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta
Correspondence and reprints: Dr Sonya MacParland, University of Toronto, 1 Kings College Circle, Toronto, Ontario M5S 3K5.  
Telephone 416-320-8339, e-mail sonyamacparland@gmail.com
Received for publication August 6, 2014. Accepted August 12, 2014
In 2013, it was estimated that there were >250,000 Canadians with chronic hepatitis C virus (HCV) infection (1). HCV infection 
causes progressive liver injury, and approximately 15% to 25% will 
develop cirrhosis, end-stage liver disease and liver cancer over a 
30-year follow-up period (2). In August 2011, two protease inhibitors 
approved by Health Canada have led to higher response rates among 
treated individuals. In December 2013, Health Canada approved the 
first polymerase inhibitor (sofosbuvir) and a new protease inhibitor with 
milder side effects than the first-generation inhibitors (simeprevir). 
These recent advances ensure that by 2014/2015, more effective and 
less toxic therapies will be available, leading to higher cure rates than 
ever before with shortened courses of therapy. However, treatment 
uptake is poor across the country, with <2% (n=3600) of the total 
population with chronic HCV treated in 2013 (1). Treatment uptake 
is limited by structural, financial, geographical, cultural and social bar-
riers. In 2013, the lifetime cost for an individual infected with HCV 
was estimated to be $64,694 (1). To maximize the impact of the highly 
effective therapies that have recently been developed, it will be 
critical to improve treatment access, which can only be achieved by 
addressing the barriers to access to HCV care in Canada, with the goal 
to reduce disease burden and, ultimately, eliminate HCV infection 
from Canada. 
Extending care to HCV-infected individuals requires a coordinated 
effort by clinicians, nurses, researchers and policy makers, and requires 
consideration of the unique needs of specific Canadian populations 
affected by HCV including people who inject drugs (PWID) and 
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Hepatitis C virus (HCV) currently infects approximately 250,000 
individuals in Canada and causes more years of life lost than any other 
infectious disease in the country. In August 2011, new therapies were 
approved by Health Canada that have achieved higher response rates 
among those treated, but are poorly tolerated. By 2014/2015, short-
course, well-tolerated treatments with cure rates >95% will be avail-
able. However, treatment uptake is poor due to structural, financial, 
geographical, cultural and social barriers. As such, ‘Barriers to access to 
HCV care in Canada’ is a crucial topic that must be addressed to 
decrease HCV disease burden and potentially eliminate HCV in 
Canada. Understanding how to better care for HCV-infected individ-
uals requires integration across multiple disciplines including research-
ers, clinical services and policy makers to address the major populations 
affected by HCV including people who inject drugs, baby boomers, 
immigrants and Aboriginal and/or First Nations people. In 2012, the 
National CIHR Research Training Program in Hepatitis C organized 
the 1st Canadian Symposium on Hepatitis C Virus (CSHCV) in 
Montreal, Quebec. The 2nd CSHCV was held in 2013 in Victoria, 
British Columbia. Both symposia were highly successful, attracting 
leading international faculty with excellent attendance leading to 
dialogue and knowledge translation among attendees of diverse back-
grounds. The current article summarizes the 3rd CSHCV, held 
February 2014, in Toronto, Ontario.
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Le 3e symposium canadien sur le virus de l’hépatite C : 
élargir les soins en cette ère de traitement sans 
interféron
Le virus de l’hépatite C (VHC), qui infecte environ 250 000 personnes 
au Canada, est responsable de plus d’années de vie perdues que toute 
autre maladie infectieuse au pays. En août 2011, Santé Canada a 
approuvé de nouvelles thérapies, dont les taux de réponse sont plus 
élevés chez les patients traités, mais qui sont mal tolérées. En 2014-
2015, des traitements de courte durée, mais bien tolérés, assurant un 
taux de guérison de plus de 95 %, seront mis en marché. Cependant, la 
participation au traitement est faible, en raison d’obstacles structurels, 
financiers, géographiques, culturels et sociaux. C’est pourquoi les 
obstacles à l’accès aux soins du VHC au Canada constituent un sujet 
essentiel, qu’il faut aborder pour réduire le fardeau du VHC et peut-
être éliminer le virus au Canada. Pour comprendre comment mieux 
soigner les personnes infectées par le VHC, il faut parvenir à intégrer 
de multiples disciplines, y compris les chercheurs, les services cliniques 
et les décideurs, afin de répondre aux besoins des principales popula-
tions atteintes du VHC, incluant les utilisateurs de drogues injectables, 
les baby-boomers, les immigrants et les personnes autochtones ou des 
Premières nations. En 2012, la Subvention nationale de formation des 
IRSC sur l’hépatite C a organisé le 1er symposium canadien sur le virus 
de l’hépatite C à Montréal, au Québec. Le 2e a eu lieu à Victoria, en 
Colombie-Britannique, en 2013. Ces deux symposiums ont obtenu un 
franc succès, car ils ont attiré des conférenciers internationaux réputés 
et suscité une excellente participation, ce qui a favorisé le dialogue et 
le partage de connaissances entre congressistes provenant de divers 
horizons. Le présent article résume le 3e symposium, qui s’est déroulé 
en février 2014 à Toronto, en Ontario.
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HCV-infected Aboriginal persons, with both groups being identified 
by the Public Health Agency of Canada (PHAC) as being at increased 
risk for new HCV infections (3,4). In February 2012, the Canadian 
Institutes of Health Research (CIHR)-based National CIHR Research 
Training Program in Hepatitis C (NCRTP-HepC) organized the 1st 
Canadian Symposium on Hepatitis C Virus (CSHCV) in Montreal, 
Quebec. The 2nd CSHCV was held in March 2013 in Victoria, British 
Columbia (5). These symposia were well attended and attracted lead-
ing international experts, leading to dialogue and knowledge transla-
tion among attendees of diverse backgrounds. The current article 
summarizes the 3rd CSHCV, held February 2014, in Toronto, Ontario, 
where new Canadian and international HCV research findings were 
presented. It also gives an overview of the multidisciplinary discussions 
centred on improving access to care for HCV-infected Canadians. 
Specifically discussed were the challenges of delivering care to special 
populations of HCV-infected persons. Also highlighted was the need 
for a Canadian HCV action plan that would guide the provision of 
prevention, care and treatment for all Canadians infected with or at 
risk for acquiring HCV. The absence of such a plan remains a major 
obstacle that limits the marshalling of resources needed for HCV-
infected Canadians to benefit from these potent, curative antivirals. 
THE NCRTP-HepC
The NCRTP-HepC is a CIHR-supported Strategic Training Initiative 
in Health Research that was first funded in 2003 (www.ncrtp-hepc.
ca/). The NCRTP-HepC is a partnership funded by public groups 
including the CIHR, PHAC and the Canadian Liver Foundation, and 
which receives private funding from both industry and community 
organizations. The main goal of the NCRTP-HepC is to build trans-
lational HCV research capacity, and to prevent, care and treat HCV 
with the desire to eliminate HCV disease in Canada within the next 
10 to 15 years. The training program uses the knowledge of 35 leading 
researchers from universities across Canada, who act as mentors for 
the trainees and who advance Canadian HCV research. The NCRTP-
HepC is interdisciplinary, with members representing diverse research 
backgrounds, including social and behavioural sciences, epidemiology 
and public health, clinical and biomedical sciences. Since 2003, the 
NCRTP-HepC has supported 71 trainees (11 MSc, 35 PhD, thee MD 
and 22 postdoctoral) and 45 summer students. This has significantly 
enhanced Canadian HCV research capacity, knowledge translation 
and interdisciplinary collaboration. 
The NCRTP-HepC is a leader in facilitating HCV research in 
Canada (5). In response to feedback from the 1st and 2nd CSHCV, 
and questionnaires completed by community groups including the 
Canadian Liver Foundation’s ‘Living with Liver Diseases’ support 
group and the Toronto Community Hepatitis C Program, the specific 
aims of the 3rd CSHCV were:
1. To facilitate transdisciplinary knowledge exchange and 
collaborations among Canadian trainees, established researchers, 
health care practitioners, health policy makers and community-
based groups working in the field of HCV. 
2. To discuss approaches that would lead to increased treatment 
uptake across the country with a focus on expanding care and 
access to difficult-to-reach populations with the ultimate goal of 
eliminating HCV in Canada. 
3. To implement, plan and deliver knowledge exchange and 
dissemination of symposium findings to support practice change, 
community awareness, harm reduction and policy development. 
4. To implement a long-term plan for sustaining an annual CSHCV.
THE 3rd CSHCV
Providing better care for HCV-infected individuals requires integra-
tion between researchers and policy makers across multiple disciplines. 
The theme of the 3rd CSHCV was “Expanding care for HCV-infected 
Individuals” and the program was divided into four sessions focusing 
on biomedical sciences, clinical sciences, social sciences, and epidemi-
ology and public health. The primary audience included Canadian 
investigators, research trainees (including MSc, PhD and postdoctoral 
fellows), health care practitioners, policy makers, industry representa-
tives and members of the affected community. The sessions, summar-
ized below, consisted of an international plenary speaker, a Canadian 
speaker and peer-reviewed original oral abstracts. 
Biomedical sciences
Advances in drug discovery and development have led to the approval 
of the first generation of direct-acting antivirals (DAAs) for the treat-
ment of HCV (1,6). Triple therapy with first-generation protease 
inhibitors significantly improved sustained virological response rates 
compared with pegylated interferon (IFN) alpha-2a and ribavirin 
alone. However, first-generation protease inhibitors are associated 
with additional side effects and complicated regimens. This has made 
treatment more successful but more difficult than previous standard 
therapy with pegylated-IFN/ribavirin (6). At the end of 2013, Health 
Canada approved the second-wave protease inhibitor (simeprevir) 
and, most significantly, the first nucleotide inhibitor of the viral poly-
merase (sofosbuvir). These developments will pave the way for 
increased availability of IFN-free anti-HCV drug regimens for 
Canadians infected with HCV.
Although IFN will largely be replaced by IFN-free DAA oral regi-
mens in the near future, IFN-based therapies may still have a role due 
to the prohibitively high cost of the new treatments. Hence, strategies 
to predict or enhance the success rate of IFN-based therapies will 
remain relevant for patient selection and, furthermore, understanding 
how IFN acts will still be of importance given its central role in the 
innate antiviral immune response. Dr Markus Heim (University 
Hospital Basel, Switzerland), a world leader on IFN as an antiviral, 
presented data from his laboratory on IFN responsiveness and dis-
cussed the future role of IFN in a world of highly effective DAAs (7). 
He suggested that most countries will develop algorithms to ensure 
that DAAs are used to treat individuals in greatest need but perhaps 
not all patients. If new treatments continue to be very expensive, he 
projected that IFN-based regimens will still have an important role, 
particularly for those who are likely to respond to therapy. Thus, it is 
critical that we gain a better understanding of why some, but not all, 
patients clear chronic HCV infections with IFN-based therapy. 
While there have been great advances in our understanding of the 
innate immune response to HCV infection, it remains unclear why 
some patients have a relatively high level of baseline activation of 
IFN-responsive genes whereas others have minimal or no activation of 
these genes despite persistent HCV infection (8). The baseline expres-
sion of IFN-responsive genes is the strongest predictor of treatment 
outcome with IFN-based therapy (9). The gene expression pattern in 
a given individual is at least partially genetically determined, with 
strong associations with variants near the IFN lambda-3 (IFNλ3) gene 
(formerly known IL-28B), as well as with the recently identified 
IFNλ4 (10-15). Patients with the treatment-unfavourable variants 
tend to have activated IFN systems before receiving treatment and 
tend to be refractory to further stimulation with IFN. Overcoming IFN 
refractoriness by combining DAAs with IFN, using alternative dosing 
strategies or other IFNs, such as IFNλ, could enhance IFN responsive-
ness, allowing for shorter, more effective treatments that may be an 
acceptable alternative to cost-prohibitive IFN-free DAA regimens.
In addition to its association with treatment outcome, the IFNλ3 
polymorphism is also associated with spontaneous resolution of acute 
HCV infection (15,16). Dr Naglaa Shoukry (Université de Montréal, 
Montreal, Quebec) discussed recent work that indicated increases in 
IFNλ3 in plasma occurring in acute HCV infection correlated with 
natural killer cell markers and degranulation (17). Natural killer cel-
lular degranulation also correlates with the magnitude of the HCV-
specific T cell responses, suggesting crosstalk between innate and 
adaptive immunity in acute HCV infection (18). A pilot transcrip-
tome analysis of peripheral blood mononuclear cells from acute HCV 
patients of the Montreal Acute Hepatitis C Cohort (HEPCO) using 
RNA sequencing will hopefully shed some light on this important 
interaction (17). Preliminary results indicate differential expression of 
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numerous genes, many of which function in innate and adaptive 
immunity. A robust induction of IFN-stimulated gene expression was 
demonstrated during acute HCV and, surprisingly, despite spontan-
eous clearance of the virus, peripheral blood mononuclear cells from 
resolver patients continued to demonstrate altered expression of 
immune genes for >1 year after clearance. Future studies will correlate 
parameters of HCV disease progression and compare these findings 
with data from patients infected with other viruses, vaccine studies 
and in vitro models. This will provide further insight into the interplay 
between innate and adaptive immunity on the outcome of HCV 
infection.
Clinical sciences
Access to care and treatment for marginalized and remotely located 
patients living with HCV is a critical issue along the cascade of care. 
Dr Sanjeev Arora, Director of Project ECHO (Extension for 
Community Healthcare Outcomes) at the University of New Mexico 
(Albuquerque, USA), described the objectives, structure, operation, 
successes and obstacles encountered with this innovative program 
(19). The mission of Project ECHO is to develop capacity to safely and 
effectively treat chronic, common and complex diseases in rural and 
underserved areas, and to monitor the outcomes of these treatments 
(20). HCV lends itself well to this model of care. Expert interdisciplin-
ary specialist teams are linked with primary care clinicians via tele-
ECHO clinics (21). Experts comanage patient cases and impart their 
expertise by way of mentorship, guidance, feedback and didactic edu-
cation. In the case of HCV, primary care physicians retain responsibil-
ity for patient management, with the ultimate goal of developing 
independent expertise allowing them to manage future patients and 
become ‘local experts’ for their peers, thereby reducing travel costs, 
wait times and improving health care quality (21). HCV care and 
expertise has been dramatically expanded to remote regions and mar-
ginalized populations including prisoners who historically had never 
received HCV treatment in New Mexico. Evaluation of this care 
model demonstrates health care provider and patient satisfaction, as 
well as cure rates that are as good, if not better, than those achieved 
within an academic setting. This approach to HCV care appears to be 
ideal for Canada but will require a willingness to demonopolize spe-
cialist knowledge, and to task shift from services traditionally provided 
by physicians to other health care providers, as well as convincing 
public payers that investing in this type of care delivery system is cost-
effective and sustainable.
In an extension of this topic, Drs Curtis Cooper and Julie Bruneau 
engaged in a lively and humorous debate entitled “Treatment should 
be strictly delivered by specialists rather than by primary care practi-
tioners in the community” (22). Dr Cooper was given the difficult task 
of representing the ‘pro’ side and presenting arguments in favour of 
specialists strictly providing HCV care (when in fact he supported a 
broader approach of primary care physician involvement). Quoting 
Hamlet as well as research on HIV and oncology care, Dr Cooper 
argued that specialists were more likely to initiate treatment and 
choose appropriate regimens when facing complex conditions. He also 
pointed out that general practitioners may lack training, expertise and 
experience to treat specific conditions for which treatment evolves 
rapidly, such as with HIV and cancer survivorship (23,24). He sug-
gested that, similar to HIV and cancer, HCV treatment is quite com-
plex and management by specialists may be required.
On the ‘con’ side, Dr Bruneau pointed out that, to reduce HCV 
morbidity and mortality, we must first and foremost substantially 
increase treatment uptake among those who are infected. Currently, 
<10% of all infected people have access to treatment (25). Conceding 
that patients with severe liver conditions or multiple comorbidities 
should be treated in specialized academic settings with skilled and 
experienced specialists, she stressed the importance of having primary 
care physicians engaged in treating HCV-infected individuals. Not 
only are primary care physicians qualified to treat HCV, they can pro-
vide testing, counselling, and treat other medical conditions that often 
coexist with HCV, such as addiction and psychiatric disorders, ultim-
ately improving the overall health outcomes (21). In the end, both 
debaters amicably concluded that HCV treatment should be widely 
available to patients according to best practices via the collaboration 
of primary care physicians and specialists in the best-adapted environ-
ment to meet individualized needs.
In further discussion regarding access to care, there was an empha-
sis on the population of HIV/HCV coinfected individuals. This group 
is a key population in Canada at risk for accelerated disease progres-
sion, and which faces multiple barriers in access to care and successful 
HCV treatment. Based on information generated from the Canadian 
Co-Infection Cohort, Dr Marina Klein (McGill University, Montreal, 
Quebec) described the current characteristics of HIV/HCV coinfected 
individuals in Canada, as well as the modifiable risk factors and inter-
ventions that could improve health outcomes (26). From 2003 to 
2013, this population had a standardized mortality rate that was 
>12-fold that of the Canadian population (27). This is driven primar-
ily by end-stage liver disease, drug overdose and malignancy. Use of 
current IFN-based HCV antiviral and HIV antiretroviral therapies 
reduces this risk for the individual but not at the general population 
level. Although HCV antiviral therapy initiation rates are higher than 
in other cohorts, females, Aboriginals and those with a history of 
crack/cocaine use were less likely to initiate treatment. HCV antiviral 
initiation rates differed considerably among the 18 sites contributing 
data to this cohort, suggesting that standardizing HCV care in coinfec-
tion should be prioritized. The value of enhanced access to HCV 
antiviral therapy was also discussed. Benefits include improved patient 
quality of life scores and reduced health care utilization following 
achievement of a sustained virological response. However, the mul-
tiple socioeconomic barriers faced by the HIV-HCV coinfected popu-
lation will need to be addressed to ensure maximum benefit. 
Social and behavioral sciences
In Canada, the majority of new and existing cases of HCV occur 
among PWID, either currently or in the past (1,28). Dr Jason Grebely 
(University of New South Wales, Australia), discussed a community-
based study of PWID in Vancouver (British Columbia) documenting 
that HCV treatment uptake was only 2% per year in 2010 (29), 
despite universal access to health care. Treatment among PWID has 
added benefits, including the potential to reduce HCV transmission. 
Treatment as prevention has the potential to markedly reduce inci-
dence and, ultimately, prevalence across the country (25,30). Clearly, 
strategies are needed to enhance HCV treatment uptake, particularly 
among PWID. 
Barriers to HCV treatment are multifactorial and include issues of 
access to therapy and barriers at the level of the patient, practitioner 
and the health care system (31-33). Dr Carla Treloar (University of 
New South Wales, Australia), explored how stigma, social exclusion, 
symbolic violence and trust could be better understood and used to 
develop more effective therapeutic encounters to address barriers to 
HCV care, particularly among PWID (34). Drawing from social theory 
and research from a number of qualitative studies with clients and prac-
titioners (35-39), she suggested some pragmatic strategies of how practi-
tioners could develop inclusive, nondiscriminatory, trust-building HCV 
services to enhance HCV assessment and treatment.
In addition to enhancing engagement to HCV care and treat-
ment, strategies to enhance responses to HCV therapy are also 
needed. Dr Louise Balfour (University of Ottawa, Ottawa, Ontario), 
highlighted the importance of adherence to HCV therapy (40). 
Specifically, Dr Balfour emphasized the important role that psycholo-
gists can play in helping to address barriers to care at the level of the 
patient, and helping to better prepare HCV patients for therapy, 
which may lead to improved adherence and, ultimately, improved 
outcomes in HCV therapy (41). Adherence will be particularly 
important with the new oral DAA regimens given the very high costs 
of failed therapy. Adherence strategies are particularly important for 
PWID or individuals with serious mental health issues (42).
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One collaborative community-based group model of care that has 
been incredibly successful for treating a highly marginalized popula-
tion was presented by Dr Jeff Powis from the Toronto Community 
Hep C program (43). This model has demonstrated that PWID can 
be engaged in HCV treatment (44) and treatment responses resemble 
those observed in clinical trials, despite the presence of multiple com-
orbidities (44,45). 
The impressive advances in the development of DAA-based ther-
apy, particularly IFN-free regimens, provide the potential to cure HCV 
infection in the vast majority of treated individuals. However, as 
shown in Figure 1, there is a considerable disparity between the poten-
tial treatment efficacy (>90%) and the current HCV treatment effect-
iveness (<10%), given that <10% of people have been treated in most 
countries, including Canada. Unless the proportion of individuals 
screened, assessed and treated for HCV infection is substantially 
increased, these anticipated therapeutic advances will have limited 
impact at the population level (46).
Epidemiology and public health
More than one-half of all existing HCV infections are estimated to be 
in current or former PWID (2,25). HCV treatment uptake in this 
population is low overall, and is especially low among current PWID 
(47-49). Barriers to HCV treatment are multifactorial and include 
issues of access to therapy and barriers at the level of the patient, prac-
titioner and the health care system (25). Active drug use and mental 
health problems are often key factors affecting HCV treatment deci-
sion by both patients and providers (25). Some of these barriers are 
associated with medication side effects, factors that affect therapy 
adherence and concerns regarding reinfection. However, there is 
ample evidence that, with appropriate care and support, PWID can be 
effectively treated for HCV, with international guidelines recom-
mending HCV treatment for PWID on a case-by-case basis (25,50). Dr 
Kim Page (University of San Francisco, California, USA), discussed 
HCV ‘treatment cascade’ in PWID and individuals with substance use 
and mental health issues, how these issues impact care delivery and 
reviewed strategies that may impact successful delivery of care in this 
population (51). She spoke of the ‘incredible shrinking patient’. After 
clinicians apply a series of criteria to exclude patients (eg, AUDIT 
score for alcohol use, depression scores, laboratory criteria and active 
injection drug use) as few as 4% of patients are deemed eligible for 
current HCV treatments. Dr Page described the UFO “You Find Out” 
study, which provides an opportunity for PWID younger than 30 years 
of age in San Francisco to undergo testing and learn if they are 
infected with HCV or HIV. The UFO model was presented as an 
example of a successful HCV education and prevention program, dem-
onstrating how integration of harm reduction, outreach, testing, edu-
cation and onsite primary care can engage and care for young injection 
drug users.
Another significant at-risk population with a high prevalence of 
HCV and low treatment uptake is the First Nations community (52). 
Dr Kathy Pouteau (Family Physician, Sioux Lookout and Kasabonika 
Lake First Nation, Ontario) shared her experiences and model for 
delivering HCV prevention and care to a remote Aboriginal commun-
ity in Northern Ontario (53). First Nations communities in 
Northwestern Ontario have seen markedly increased rates of HCV 
infection. Risk factors for infection include injection drug use and, in 
2009, the Chiefs of the Nishnawbe Aski Nation declared a state of 
emergency around prescription drug use in their communities. Dr 
Pouteau discussed the challenges, opportunities and collaborative 
response of health service providers and First Nations in rural and 
remote communities in the Sioux Lookout area. Barriers to HCV pre-
vention, diagnosis and care in these communities include fragmented 
primary and public health systems, limited access to harm reduction 
programs, difficulties in confirming HCV diagnosis and accessing post-
test counselling, limited access to HCV support and treatment, bar-
riers due to intergenerational and personal trauma as well as ongoing 
inequities in social, economic and political determinants of health. 
These barriers are being addressed by health care providers in First 
Nations communities using a collaborative approach. This approach 
centres around five main priorities: building political advocacy and 
support; encouraging communication and collaboration with health 
services agencies; establishing meaningful partnerships based in First 
Nations communities (ie, opioid substitution programs); building First 
Nations HCV capacity, local ‘expert’ resources and tertiary partner-
ships; and promoting culturally safe and trusting relationships between 
health care providers and community members. 
A critical player in the national response to HCV is PHAC. One 
of the challenges facing policy makers is the limitations in the compre-
hensiveness of HCV surveillance data in Canada, which makes it 
highly challenging to estimate the HCV disease burden. Dr Maxim 
Troubnikov from PHAC presented an updated model for determining 
estimates of the prevalent and undiagnosed HCV infections in 
Canada in 2011 (54). This model followed approaches used by the 
Center for Communicable Diseases and Infection Control (CCDIC) 
to estimate the 2011 HCV disease burden using the workbook and the 
back-calculation modelling methods. Using the workbook method, 
preliminary results, based on a Canadian population of 34,483,975, 
estimated that the anti-HCV+ prevalence for 2011 was 0.96% (95% 
CI 0.61 to 1.34), corresponding to 331,046 persons (95% CI 210,352 
to 462,085 persons), while the chronic HCV prevalence was 0.71% 
(95% CI 0.45% to 0.99%), corresponding to 244,836 persons (95% CI 
155,177 to 341,391 persons). It was further estimated that 44% of 
anti-HCV-positive persons were likely undiagnosed in 2011, although 
before having a final estimate, input from the back-calculation process 
and validation is required.
The second PHAC presentation, by Dr Margaret Gale-Rowe of the 
CCDIC, outlined the actions and the current federal response to HCV 
prevention and control (55). The current PHAC response includes 
HCV research collaboration and support, active disease surveillance 
and epidemiology, as well as the development of professional guide-
lines and resources for the management of HCV (56). Workshops and 
studies held by PHAC over the past year include discussion of birth 
cohort screening for HCV, a topic that was debated in the 2nd 
CSHCV (5). As a result, there is an interim statement that is under 
development on HCV screening based on the birth cohort approach 
in addition to current risk-based screening. Programs and partnerships 
Figure 1) The disparity between potential hepatitis C virus (HCV) treat-
ment efficacy and projected HCV treatment effectiveness. High efficacy of 
HCV treatment is projected over five to 10 years. Sustained virological 
response (SVR) has increased from 40% with interferon (IFN) and riba-
virin (RBV) in 1998, 55% with pegylated-IFN (PEG-IFN) and RBV in 
2002, approximately 70% in the era of PEG-IFN, RBV, and a protease 
inhibitor in 2012 (genotype 1 only; patients with HCV genotype 2 or 3 will 
still have an SVR of approximately 80% with PEG-IFN-RBV) and IFN-
free regimens are anticipated to be available by 2018, with an expected SVR 
of 90%. However, the global effects of new treatments are negligible without 
expanded access given the low treatment uptake among individuals with 
HCV infection (57-59). Reproduced with permission from reference 25
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that PHAC has fostered include promoting public and professional 
awareness campaigns including World Hepatitis Day and funding for 
the expansion of HCV knowledge including funding for the NCRTP-
HepC and the Global Hepatitis C Technical Network. The current 
PHAC response to HCV was outlined and presently exists as part of an 
integrated response to sexually transmitted and blood borne infections 
including HIV, HCV and other infections. In the discussion period 
following these presentations, there was discussion about the need for 
a unified national strategy for hepatitis C in Canada. Although the 
PHAC representatives acknowledged the value of such an approach, 
no concrete plans to develop a national strategy currently exist.
OUTCOMES OF THE 3rd CSHCV
Although current treatments for HCV are effective, the severe side 
effect profile, prolonged duration, need for specialized support and the 
high cost, greatly limit treatment uptake. By 2014/2015, it is likely 
that all-oral, well-tolerated HCV treatment will be available with cure 
rates >95% in treated individuals. These new treatments will dramat-
ically improve the ability to initiate treatment and cure those infected. 
However, translating these remarkable therapeutic improvements into 
tangible reductions in disease morbidity and mortality will require 
significant improvements in treatment uptake. With this in mind, the 
major focus on HCV in Canada will likely shift from the drug discov-
ery to developing strategies to engage people into care and treatment. 
The 3rd CSHCV highlighted strategies that have proven effective in 
increasing treatment uptake internationally and nationally, with a 
focus on practical implementation of successful approaches in Canada.
The challenges of increasing HCV treatment uptake in Canada are 
structural, financial, geographical, cultural and social. It is time to 
develop achievable goals of treating the four major population groups 
in Canada that are most affected – PWID, baby boomers, immigrants 
and Aboriginal/First Nations people – so that HCV in Canada can be 
eliminated within the next 10 to 15 years. Among those at risk, PWID 
will require a specific focus for harm reduction to prevent reinfection. 
Without a screening program to identify those who remain undiag-
nosed, disease elimination will not be achieved. It will be critical to 
confirm whether the preliminary PHAC estimate that 44% of 
Canadians are unaware of their infection is correct. The key topic of 
discussion at this symposium was whether HCV care should be strictly 
provided by subspecialist clinicians or whether primary care physicians 
should treat HCV-infected individuals. The issues raised were the 
complexity of HCV treatment regimens in addition to the fact that, if 
all HCV-infected individuals were to be treated, there would not be a 
sufficient number of subspecialists to fill the need. The broad consen-
sus was that a blended model of care, including many health care 
disciplines, will be required to maximize identification, treatment 
initiation and HCV cure. The notion of employing the ECHO model 
of telemedicine to reach geographically isolated areas was presented, a 
model that has been especially effective in providing HCV care in 
remote areas of the United States (21).
This symposium highlighted that given the unique challenges of 
the HCV epidemic and the imminent potential for curability, there is 
a clear need for national coordination of HCV prevention, care and 
treatment. National strategies have been adopted in countries, such as 
Australia, Scotland and the United States, which have resulted in 
improvements in HCV prevention, care and treatment (5). Canada 
needs a national strategy or action plan so that Canadians can also 
benefit from the imminent curability of HCV so that disease elimina-
tion within the next 10 to 15 years can become a realized dream.
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